AVS Enrolls First Patient in First-in-Human Study for Coronary Intravascular Lithotripsy
Amplitude Vascular Systems (AVS), now part of Stryker, has announced the enrollment of its first patient in the POWER CAD I study, which is the first-in-human trial for its Pulsatile Intravascular Lithotripsy (PIVL) therapy targeting severely calcified coronary arteries. The study aims to assess the feasibility of the Pulse IVL™ System in treating coronary artery diseases.
BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, today announced the enrollment of the first patient in its first-in-human (FIH) study for Pulsatile Intravascular Lithotripsy (PIVL) therapy in a coronary indication. The POWER CAD I study will evaluate the feasibility of the Pulse IVL™ System for the treatment of patients with moderate to severely calcified coronary arteri